Related references
Note: Only part of the references are listed.Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer
Francis Worden et al.
ENDOCRINE-RELATED CANCER (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS Thyroid effects of tyrosine kinase inhibitors
Frederic Illouz et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Cisplatin based chemotherapy in patients with advanced differentiated thyroid carcinoma refractory to I131 treatment
Osama Hussein et al.
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY (2013)
GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma
Jean-Philippe Spano et al.
MEDICAL ONCOLOGY (2012)
Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
Laurie L. Carr et al.
CLINICAL CANCER RESEARCH (2010)
Cytotoxic Chemotherapy for Differentiated Thyroid Carcinoma
S. I. Sherman
CLINICAL ONCOLOGY (2010)
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Keith C. Bible et al.
LANCET ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
Martin J. Schlumberger et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
David S. Cooper et al.
THYROID (2009)
Ergebnisse der Chemotherapie des Schilddrüsenkarzinoms*
G. Benker et al.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2008)
Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium
A. Matuszczyk et al.
HORMONE AND METABOLIC RESEARCH (2008)
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
Ezra E. W. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Motesanib diphosphate in progressive differentiated thyroid cancer
Steven I. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer
Athanassios Argiris et al.
INVESTIGATIONAL NEW DRUGS (2008)
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy
C. Durante et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
Furio Pacini et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer
F Santini et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Share Paper
